Press release | Official website vaccine against COVID-19 Sputnik V.

Main
Newsroom
Press Releases

Press Releases

Sputnik V demonstrates 94.8% efficacy against COVID during the vaccination campaign in San Marino

Press release, 02.09.2021

A new study in Argentina on Sputnik V: “Our observations suggest that protection increases over 6 months following vaccination as a consequence of antibody maturation, resulting in improved potency of antibodies to viral escape mutations.”

Press release, 25.08.2021

Indonesia becomes the 70th country to approve the Sputnik V vaccine

Press release, 25.08.2021

The single-component Sputnik Light vaccine authorized in Philippines

Press release, 23.08.2021

A combination between AstraZeneca and the first component of Sputnik V vaccine (Sputnik Light) demonstrates high immunogenicity profile during the clinical study in Azerbaijan

Press release, 20.08.2021

Real-world data shows one shot Sputnik Light vaccine (the first component of the Sputnik V vaccine) has high safety and 93.5% efficacy against COVID during vaccination in Paraguay

Press release, 17.08.2021

Laboratorios Richmond delivers the first batch of over 1 million doses of the Sputnik V vaccine produced in Argentina to the country’s Ministry of Health

Press release, 12.08.2021

The Russian Direct Investment Fund: on the first anniversary of Sputnik V registration official data from leading countries confirms the vaccine’s high safety and efficacy profile

Press release, 11.08.2021

Argentina and Russia continue to successfully work together to accelerate the vaccination campaign and generate scientific evidence regarding the interchangeability of vaccines

Press release, 04.08.2021

Combination of the first component of Sputnik V vaccine (Sputnik Light vaccine) with vaccines by AstraZeneca, Sinopharm and Moderna demonstrates high safety profile during the study in Argentina’s Buenos-Aires province

Press release, 04.08.2021

4 5 6 7 8